Onconetix on Thursday said it named its interim Chief Financial Officer, Karina Fedasz, as interim Chief Executive Officer, effective immediately. Also on Thursday, the biotechnology company said ...

Onconetix, Inc., (Nasdaq: ONCO) ("Onconetix" or the “Company”), (formerly Blue Water Biotech, Inc. (BWV)), a cancer ...

Onconetix (ONCO) announced that new clinical data of Proclarix was presented on March 23, 2025 during the 2025 European ...

Onconetix, Inc. (formerly Blue Water Biotech, Inc.) has announced the presentation of new clinical data for Proclarix® during the 2025 European Association of Urology congress, showcasing its ...

Onconetix, Inc., (Nasdaq: ONCO) ("Onconetix" or the “Company”), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development ...

CINCINNATI - Onconetix, Inc. (NASDAQ:ONCO), a cancer diagnostics company currently trading at $0.13 per share with a market cap of just over $1 million, presented new clinical data for its ...

The company states: “Onconetix (ONCO) announced that new clinical data of Proclarix was presented on March 23, 2025 during the 2025 European Association of Urology congress, which data further ...

Onconetix, Inc., formerly Blue Water Biotech, announced that an abstract has been accepted for presentation at the 2025 European Association of Urology congress in Madrid. The presentation will ...